Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00060398 · ClinicalTrials.gov registry record · Phase 3
Epoetin Alfa With or Without Dexamethasone in Treating Fatigue and Anemia in Patients With Hormone-Refractory Prostate Cancer
A Phase 3 study of Prostate Cancer and Fatigue, sponsored by Eastern Cooperative Oncology Group.
- Completed
- Registry status
- Phase 3
- Development phase
- 282
- Enrollment target
- 20
- Study locations
NCT00060398 is a Phase 3 study of Prostate Cancer and Fatigue that has completed, run by Eastern Cooperative Oncology Group. The registered enrollment target is 282 participants, below the 608-participant average among 735 other Prostate Cancer trials with a reported enrollment target (54% lower). The trial reports 20 study locations across 5 states.
The verdict
NCT00060398, a Phase 3 study of Prostate Cancer and Fatigue, has completed, sponsored by Eastern Cooperative Oncology Group.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 282 participants
- Enrollment target
- 20
- Study locations
Study Summary
RATIONALE: Epoetin alfa may stimulate red blood cell production and may help improve cancer-related anemia and fatigue. Steroid therapy with dexamethasone may increase the effectiveness of epoetin alfa. It is not yet known if epoetin alfa is more effective with or without dexamethasone in treating anemia-related fatigue in patients with prostate cancer. PURPOSE: This randomized phase III trial is studying epoetin alfa and dexamethasone to see how well they work compared to epoetin alfa alone in treating anemia-related fatigue in patients with prostate cancer that is refractory to treatment with hormone therapy.
Conditions Studied
Interventions
- DRUG dexamethasone
- BIOLOGICAL epoetin alfa
Study Locations (20)
Colorado
- Aurora Presbyterian Hospital - Aurora
- Boulder Community Hospital - Boulder
- Penrose Cancer Center at Penrose Hospital - Colorado Springs
- Porter Adventist Hospital - Denver
- Presbyterian - St. Luke's Medical Center - Denver
- St. Joseph Hospital - Denver
- Rose Medical Center - Denver
- CCOP - Colorado Cancer Research Program, Incorporated - Denver
- Swedish Medical Center - Englewood
- Sky Ridge Medical Center - Lone Tree
- Hope Cancer Care Center at Longmont United Hospital - Longmont
- St. Mary-Corwin Regional Medical Center - Pueblo
- North Suburban Medical Center - Thornton
Illinois
- Rush-Copley Cancer Care Center - Aurora
- Robert H. Lurie Comprehensive Cancer Center at Northwestern University - Chicago
- Hematology and Oncology Associates - Chicago
Georgia
- Winship Cancer Institute of Emory University - Atlanta
- Veterans Affairs Medical Center - Atlanta (Decatur) - Decatur
California
- Memorial Medical Center Cancer Services - Modesto
Florida
- H. Lee Moffitt Cancer Center and Research Institute at University of South Florida - Tampa
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 282 participants |
| Start Date | 2004-09-29 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00060398
The ClinicalTrials.gov registry entry for NCT00060398 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 282 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 608-participant average among 735 other Prostate Cancer trials with a reported enrollment target (54% lower). The listed sponsor is Eastern Cooperative Oncology Group, which has 141 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Prostate Cancer appearing as the primary indexed condition, and to 2 interventions - of which dexamethasone is the first listed.
NCT00060398 reports 20 study locations spanning 5 distinct geographic areas - top geographies include Colorado, Illinois, Georgia.
Frequently Asked Questions
What is clinical trial NCT00060398 about?
NCT00060398 is a clinical study titled "Epoetin Alfa With or Without Dexamethasone in Treating Fatigue and Anemia in Patients With Hormone-Refractory Prostate Cancer". RATIONALE: Epoetin alfa may stimulate red blood cell production and may help improve cancer-related anemia and fatigue. Steroid therapy with dexamethasone may increase the effectiveness of epoetin alfa. It is not yet known if epoetin alfa is more effective with or without dexamethasone in treating a...
What is the current status of trial NCT00060398?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 282 participants. The study started on 2004-09-29.
What conditions does trial NCT00060398 study?
This clinical trial studies the following conditions: Prostate Cancer, Fatigue, Anemia.
What interventions are being tested in trial NCT00060398?
The interventions under investigation include: dexamethasone (DRUG), epoetin alfa (BIOLOGICAL).
Who is sponsoring clinical trial NCT00060398?
This trial is sponsored by Eastern Cooperative Oncology Group, which has 141 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00060398 being conducted?
This trial has 20 study locations across California, Colorado, Florida, Georgia, Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Prostate Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Copper Cu 64 PSMA I&T PET Imaging in Men With Newly Diagnosed Prostate Cancer
RECRUITING · Phase 3
-
PROSTATE-IQ: Parallel RandOmized STudy of Personalized Apalutamide Treatment and Evaluation to Improve Quality of Life in Post-Operative Radiation With Androgen Axis Suppression. A Phase III Multi-center Study for Men With Detectable PSA After Prostatectomy for Prostate Cancer.
RECRUITING · Phase 3
-
Androgen Suppression Combined With Nodal Irradiation and Dose Escalated Prostate Treatment
RECRUITING · Phase 3
-
Robotic Opioid-free Prostatectomy Enhanced Strategy (ROPES)
RECRUITING · Phase 3
-
SAFE Nerve Sparing Guided by Micro-ultrasound (MUS)
RECRUITING · Phase 3
-
Adjuvant Curcumin to Assess Recurrence Free Survival in Patients Who Have Had a Radical Prostatectomy
RECRUITING · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.